Recent Updates
Recently added Catalysts
LNTH Positive Sentiment

Lantheus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Tuesday, September 2, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantheus Holdings, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9. CEO Brian Markison will lead the presentation, which can be accessed via the company's website. A replay will be available for 30 days post-event, showcasing Lantheus's commitment to radiopharmaceutical advancements.
Price reaction · baseline $54.9 (2025-08-29 close) · hit pre-market · clean, no other LNTH news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lantheus is committed to improving patient outcomes.
  • The presentation at a major healthcare conference highlights their leadership.
  • Access to the live webcast increases transparency and engagement.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
2%
average across 7 past catalysts
Lead asset
18F-DCFPyL
Phase 3 · Prostate Cancer

Full Press Release Details

BEDFORD, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 23rdAnnual Global Healthcare Conference at 7:00 a.m. ET on Tuesday, September 9.
To access the live webcast of the presentation, please visit the Investors section of the Company’s website atwww.lantheus.com. A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.
About LantheusLantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden and Switzerland, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visitwww.lantheus.com.

Contacts:Mark KinarneyVice President, Investor Relations978-671-8842ir@lantheus.com

Frequently Asked Questions

When will Lantheus present at the conference?

Lantheus will present on September 9, 2025, at 7:00 a.m. ET.

Who is presenting for Lantheus?

Brian Markison, the Chief Executive Officer, will present.

How can I access the presentation?

The live webcast can be accessed on Lantheus's website.

Will there be a replay of the presentation?

Yes, a replay will be available for at least 30 days after the event.

ShareAdd on Google
Tags: LNTH Viatris Investor Conferences Healthcare Lantheus Morgan Stanley healthcare conference radiopharmaceuticals patient outcomes
Last updated: Sep 2, 2025

Biotech snapshot

Cash runway
$593M liquidity · $0M/mo burn
Low dilution risk
Lead asset
18F-DCFPyLPhase 3
Prostate Cancer →

Catalyst track record

+48%
best trade around LNTH's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for LNTH.

See every catalyst's timing & PoA →